RNS Number:4985N
Antisoma PLC
14 July 2003

AACR presentation highlights possible new cancer targets for Antisoma's DMXAA

14 July 2003, London, UK - A team led by Professor Lloyd Kelland, Head of
Laboratory at Antisoma plc (LSE:ASM, NASDAQ-Europe:ASOM), yesterday presented
the latest work on the company's vascular targeting agent DMXAA at the American
Association of Cancer Research meeting in Washington, USA.

The work highlights the possibility that DMXAA could be used as part of
improved, combination regimens for pancreatic and colon cancers. Human tumour
grafts representing these cancer types were grown in immune-deficient mice.
Treatment with DMXAA alone slowed the growth of both types of tumour. More
importantly, when DMXAA was given together with leading current therapies -
gemcitabine for pancreatic cancer and irinotecan for colon cancer - the effect
of the combination on tumour growth was additive or greater.

The team also reported similar findings for DMXAA combined with paclitaxel in
two human graft models of non-small cell lung cancer, building on earlier
reports of a synergistic interaction between DMXAA and paclitaxel in other
tumour models.

Glyn Edwards, CEO of Antisoma said 'The latest DMXAA results are another
encouraging signal of the potential value of this drug in combination settings
across a wide range of solid tumours. Pancreatic cancer is a poorly treated
disease where we could expect to gain orphan drug status, so this indication
could provide a high-speed route to a product licence for DMXAA.'

Enquiries:

Antisoma plc
Daniel Elger                                         Tel: +44 (0)20 8799 8200
Head of Corporate Communications

Financial Dynamics
Jonathan Birt                                        Tel: +44 (0)7884 238952

About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the pre-clinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma signed a ground-breaking collaboration agreement with Roche to
develop and commercialise products from Antisoma's pipeline. Visit
www.antisoma.com for further information about Antisoma.



DMXAA

DMXAA was discovered by Professors Bruce Baguley and William Denny and their
teams at the Auckland Cancer Society Research Centre ("ACSRC"), University of
Auckland, New Zealand.. Two phase I clinical trials, sponsored by the Cancer
Research Campaign in the UK and in New Zealand, have provided safety data and
indicate that DMXAA causes a reduction in tumour blood flow when used alone. A
third phase I study is currently ongoing. DMXAA was in-licensed by Antisoma from
Cancer Research Ventures Limited ("CRV") in August 2001 and marketing rights
have been licensed to Roche under the broad agreement signed with Antisoma in
November 2002.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESDGGMNVDZGFZG